Mayo Foundation for Medical Education and Research

University of Illinois

University of Leeds

Leeds University

University of Central Florida Research Foundation Inc

Jose S Pulido

Richard G Vile

Peter Selby

Timothy J Kottke

Alan A Melcher

Kiminobu Sugaya

Tingyu Qu

Ankur V Vaghani

Christopher Brannen

Hojoong M Kim

Jill M Thompson

Xiajing Dong

Raymond Iezzi

Jarel K Gandhi

Alan D Marmorstein

Russell J Hamilton

Asrar B Malik

Shahid Siddiqui

Gregory L Walker

Rosa Maria Diaz

Nalin M Kumar

Christine Marie Pulido

Beatrice Yue

This document provides methods and materials for performing retinal pigment epithelium transplantation. For example, methods and materials for using fibrin supports for retinal pigment epithelium transplantation are provided.

Methods and materials for using fibrin supports for retinal pigment epithelium transplantation

This document provides methods and materials related to treating cancer. For example, methods and materials for using nucleic acid libraries to treat cancer are provided.

Methods and materials for treating cancer

This document provides methods and materials for treating cancer. For example, methods and materials for treating cancer using combinations of antigens are provided. For example, VSV vectors designed to express a GNAQ antigen, a TYRP1 antigen, and an N-RAS antigen can be used to reduce the number of cancer cells (e.g., uveal melanoma cells) within a mammal (e.g., a human). In some cases, VSV vectors designed to express a BRAF antigen, a TOPO-11a antigen, and a YB-I antigen can be used to reduce the number of cancer cells (e.g., skin melanoma cells) within a mammal (e.g., a human). The composition can comprise less than 50 separate nucleic acid molecules.

This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors (e.g., gliomas) within a mammal (e.g., a human) are provided.

This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors (e.g., gliomas) within a mammal (e.g., a human) are provided. In general, one aspect of this document features a composition comprising, or consisting essentially of, nucleic acid encoding HIF-2a, SOX-10, C-MYC, and TYRP-1, wherein the composition comprises less than 100 separate nucleic acid molecules.

This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors within a mammal (e.g., a human) are provided.

This invention provides methods for preparing novel mammalian multipotent stem cells (MSCs), compositions thereof, and methods of preparing and administering the cells.

Mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof

The present application is directed to siRNA-based silencing of the type II receptor of TGF&#x3b2;. siRNAs that target this receptor abrogate the receptor protein and transcript, TGF&#x3b2;-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory response and matrix deposition. These findings show that siRNAs can be successfully delivered both in vitro and in vivo to regulate the TGF&#x3b2; type II receptor level and modulate wound response. Methods and compositions exploiting the findings of the present invention have a wide-ranging application, extending from treatment of disorders of the eye to other organs and tissues throughout the body.

Silencing of TGF&#x3b2; type II receptor expression by siRNA

This invention relates to novel mammalian multipotent neural stem cells (MNSCs), compositions thereof, and methods of preparing and administering the cells to diseased, aged or damaged tissue such that the cells properly migrate and differentiate and a neurological or corporal deficit is improved or remedied as a result.

Mammalian multipotent neural stem cells and compositions, methods of preparation and methods of administration thereof

An ocular brachytherapy device, generally comprising a catheter and wire, impregnated with radioactive material, are provided. The wire is formed having a desired treatment shape and size such that it can be placed near an area requiring treatment and effectuate treatment while not affecting adjacent areas. For ease in placement near such areas the wire is preferably formed using materials having properties that permit formation into a desired shape while allowing the wire to be straightened for retraction into the catheter, the shape returning upon removal from the catheter. The wire is preferably impregnated with radioactive material. When the catheter is placed near the area of treatment and the wire is pushed out of the catheter, the wire retakes the desired form and provides a therapeutic radioactive treatment to the area. Preferably, the radioactive material is placed on one edge of the wire, such that the radiation can be directed to the affected area, and non-affected areas can be shielded from radiation.

Growing community of inventors

Rochester, MN, United States of America

Jose S Pulido